Drug intelligence / Profile preview

KOBACAR

Development stage: Unknown
Lead developer: Septalyst Lifesciences
Modality: Peptides
Administration: Oral

Overview

**KOBACAR** is a marketed oral fixed-dose neuroprotective nutritional formulation from Septalyst Lifesciences for post-stroke recovery, dementia, and neurodegenerative diseases. The sponsor describes the tablet formulation as containing L-carnosine 200 mg and Ginkgo biloba extract 60 mg, with claimed antioxidant, anti-apoptotic, cognition-supporting, and neuroprotective effects; no specific molecular target or clinically validated mechanism is publicly identified. ([septalyst.com](https://www.septalyst.com/products/neurology/neuro_degeneration/kobacar))

Brand names: KOBACAR

Beyond the preview

Go deeper on KOBACAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOBACAR.

Explore the full profile